| A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST） (NCT07010419) | Allist Pharmaceuticals, Inc. | 2025-05-28 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NCT06955988) | Allist Pharmaceuticals, Inc. | 2025-03-04 |
| Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation (NCT06956001) | Allist Pharmaceuticals, Inc. | 2024-11-19 |
| A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases (NCT06970639) | Allist Pharmaceuticals, Inc. | 2024-09-26 |
| JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation (NCT06416410) | Allist Pharmaceuticals, Inc. | 2024-08-07 |
| A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects (NCT06162169) | Allist Pharmaceuticals, Inc. | 2023-11-25 |
| A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. (NCT06008288) | Allist Pharmaceuticals, Inc. | 2023-10-27 |
| Mass Balance Study of [14C]JAB-21822 (NCT05920941) | Allist Pharmaceuticals, Inc. | 2023-07-08 |
| A Food Effect Study of JAB-21822 in Healthy Subjects (NCT05875493) | Allist Pharmaceuticals, Inc. | 2023-05-12 |
| Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion (NCT05466149) | Allist Pharmaceuticals, Inc. | 2022-09-27 |
| A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 (NCT05276726) | Allist Pharmaceuticals, Inc. | 2022-08-17 |
| Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation (NCT05288205) | Allist Pharmaceuticals, Inc. | 2022-04-14 |
| JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation (NCT05194995) | Allist Pharmaceuticals, Inc. | 2022-02-17 |
| Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation (NCT04958967) | Allist Pharmaceuticals, Inc. | 2021-10-01 |
| A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China (NCT05009329) | Allist Pharmaceuticals, Inc. | 2021-07-26 |
| To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (NCT04853342) | Allist Pharmaceuticals, Inc. | 2021-06-07 |
| JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors (NCT04720976) | Allist Pharmaceuticals, Inc. | 2021-03-23 |
| Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation (NCT04858958) | Allist Pharmaceuticals, Inc. | 2020-08-10 |
| A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China (NCT04121286) | Allist Pharmaceuticals, Inc. | 2020-07-14 |
| Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG） (NCT03787992) | Allist Pharmaceuticals, Inc. | 2019-05-30 |
| Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers (NCT03941340) | Allist Pharmaceuticals, Inc. | 2019-04-08 |
| Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers (NCT03926182) | Allist Pharmaceuticals, Inc. | 2019-02-19 |
| Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M (NCT03452592) | Allist Pharmaceuticals, Inc. | 2018-04-30 |